You searched for "PCa"

182 results found

Adjuvant radiotherapy versus wait-and-see after radical prostatectomy

Optimum treatment modalities in prostate cancer continue to evolve, with debates at each stage of the evolution process, from focal therapy to radical treatment. In this randomised study, Wiegel et al. investigated the role of adjuvant radiotherapy following open radical...

Factors and time to conversion from prostate cancer active surveillance to treatment

Active surveillance is the standard of care for men with low-risk and selected men with favourable intermediate risk prostate cancer. The aim is to reduce the morbidity and mortality of overtreatment of non-clinically significant prostate cancer. A significant proportion progress...

Preoperative risk stratification of high-risk prostate cancer patients

High-risk prostate cancer (HRPCa) is associated with a significant risk of recurrence after radical treatment. While several classification systems exist, the D’Amico criteria – based on clinical T stage ≥T2c, prostate specific antigen (PSA) ≥20 ng/mL, or Gleason score (GS)...

Updated guide on integrated paediatric continence services to significantly improve children’s lives and save NHS cost

The Paediatric Continence Forum has recently launched its updated Guide on how to commission and run integrated, nurse-led, community-based paediatric bladder and bowel (continence) services. These are clinically effective, improve the lives of children and their families and generate significant...

UTI Diagnostics: A Practitioner’s Guide to the Testing Landscape

Join Bladder Health UK for an independent CPD-style webinar exploring the evolving diagnostic landscape for urinary tract infections. With expert insights from Gabrielle Gleeson‑Solomon and Nick Parkinson PhD (Tota), this session will help clinicians navigate the complexities of UTI testing,...

Join Prostate Cancer Research Free Webinar for Healthcare Professionals

Managing Sexual Side Effects After Prostate Cancer: A Patient & Therapist Perspective Date: 20 January 2026 — 6.00pm (London)Register: https://zoom.us/webinar/register/WN_CstOkvaUSNSg_xlFI1Z27w Why attend?Sexual side effects remain one of the most challenging and under-discussed consequences of prostate cancer treatment. This focused webinar...

PCUS Annual Conference 2026

Primary Care Urology Society

Prostate cancer

Case 1 What is prostate specific antigen (PSA) and what is its function? According to the ERSPC Trial (at 13 years), what was the number needed to screen and diagnosed to prevent one prostate cancer death and what was the...

Performance of non-invasive tests in diagnosing BOO in men with LUTS

A large proportion of urology involves the treatment of bladder outflow obstruction (BOO) in men. Yet BOO in men is very difficult to accurately quantify with the only regular non-invasive test being uroflowmetry. Pressure flow urodynamics may be considered the...

Malignant upper urinary tract obstruction: emergency presentations and long-term outcomes

Malignant upper urinary tract obstruction (MUUTO) is a frequent emergency urological referral, often necessitating kidney drainage to preserve renal function. However, many patients have advanced cancer with limited life expectancy, raising questions about intervention benefits. While percutaneous nephrostomy (PCN) or...

Five-year outcomes following negative MRI or biopsy in the RAPID diagnostic pathway

The Rapid Assessment for Prostate Imaging and Diagnosis (RAPID) pathway was introduced in UK urology centres to streamline prostate cancer diagnosis using an MRI-directed approach. Men with elevated PSA undergo upfront multiparametric MRI (mpMRI), and biopsy is reserved for those...

The Future of Prostate Cancer Imaging: What’s Next?

The pioneering charity Prostate Cancer Research convened industry leaders, NHS experts and patients for a webinar exploring how artificial intelligence (AI) is transforming prostate cancer imaging and clinical pathways. The session provided valuable insights for healthcare professionals seeking innovative approaches...